Chimerin 1 (CHN1)

Chimerin 1 (CHN1) is a GTPase-activating protein (GAP) for RAC GTP-binding proteins—including Rac1 and Cdc42—belonging to the chimaerin family of RhoGAPs[1][3]. It is predominantly expressed in the nervous system, particularly in the brain, where it regulates neuronal signal transduction, axon pathfinding, and cytoskeletal arrangement by inactivating Rac1 through its GAP activity[1][2][3]. CHN1 contains an N-terminal SH2 domain, a central C1 domain (homologous to protein kinase C), and a C-terminal RhoGAP domain that interacts with targets upon lipid signaling (notably, diacylglycerol binding facilitates membrane localization and function)[1]. Germline gain-of-function mutations in CHN1 are a well-established cause of isolated Duane retraction syndrome (a congenital cranial dysinnervation disorder caused by abnormal ocular motor axon development)[2][3]. In oncology, CHN1 overexpression is associated with poor prognosis and aggressive tumor biology—particularly in gastric and cervical cancers, where it promotes migration, invasion, and epithelial-mesenchymal transition (EMT)[3][4]. CHN1 is emerging as a diagnostic and prognostic biomarker for certain cancers, and its interaction with immune infiltrates may influence the effectiveness of immunotherapy; CHN1 or its regulators are potential, though as yet investigational, therapeutic targets in cancer[4]. No clinically approved drugs are known to directly target Chimerin 1 as of the current literature, and there are currently no well-established mechanisms of drug action or safety profiles specific to pharmacological CHN1 inhibition[4]. However, its roles in neurodevelopment and cancer highlight both its therapeutic potential and safety liabilities related to fundamental cellular processes.

Other names

N-chimaerinalpha-1-chimaerinn-chimerinARHGAP2CHNRhoGAP2DURS2NCRho GTPase-activating protein 2a2-chimaerinchimaerin 1A-chimaerinalpha-chimerin